| Yang, Bin |
NCT05312268: Rasburicase Treatment in Chronic Gouty Arthritis |
|
|
| Recruiting | 4 | 60 | RoW | Rasburicase | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Chronic Gout | 10/24 | 04/25 | | |
NCT04875169: Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis |
|
|
| Completed | 3 | 336 | Canada, RoW | Core Treatment Active Experimental: SHR0302 Dose#1, Core Treatment Active Experimental: SHR0302 Dose#2, Core Treatment Placebo Comparator: Placebo, Extension Treatment Active Experimental: SHR0302 Dose#1, Extension Treatment Active Experimental: SHR0302 Dose#2 | Reistone Biopharma Company Limited | Atopic Dermatitis | 08/22 | 05/23 | | |
NCT05470413: Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata |
|
|
| Active, not recruiting | 3 | 330 | RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Alopecia Areata | 10/23 | 02/24 | | |
NCT06281561: Dexmedetomidine Premedication for Post-anaesthesia Sleep Disturbance |
|
|
| Not yet recruiting | 3 | 110 | NA | Normal Saline, Dexmedetomidine | The First Affiliated Hospital of Xiamen University | Postoperative Sleep Disturbance | 11/24 | 12/24 | | |
NCT06552520: To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Not yet recruiting | 3 | 500 | RoW | TQH2722 injection, Placebo of TQH2722 injection | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Atopic Dermatitis | 10/25 | 06/26 | | |
NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
MARBLE-23, NCT04717310: Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis |
|
|
| Active, not recruiting | 2/3 | 645 | RoW | SHR0302 Ointment, SHR0302 Ointment 2%, SHR0302 Ointment 1%, SHR0302 Ointment 0.5%, Vehicle, Placebo | Reistone Biopharma Company Limited | Atopic Dermatitis | 09/23 | 07/24 | | |
| Recruiting | 2 | 80 | RoW | Activated CIK, CIK | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital | Advanced Liver Cancer | 01/21 | 01/21 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
| Completed | 2 | 93 | RoW | 611 Q2W, 611 Q4W, Matching placebo, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Dermatitis, Atopic | 07/23 | 09/23 | | |
NCT06228560: Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment |
|
|
| Recruiting | 2 | 200 | RoW | LP-003, Placebo, Omalizumab | Longbio Pharma | Chronic Spontaneous Urticaria | 01/25 | 01/25 | | |
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 160 | RoW | TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Atopic Dermatitis | 03/24 | 03/24 | | |
| Recruiting | 2 | 159 | Europe, Canada, Japan, US, RoW | GSK1070806 | GlaxoSmithKline | Dermatitis, Atopic | 11/29 | 11/29 | | |
NCT05999799: A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Recruiting | 2 | 175 | Europe, Canada, Japan, US, RoW | GSK1070806, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 08/24 | 06/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05713110: A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma |
|
|
| Recruiting | 2 | 140 | RoW | tazemetostat, HMPL-689 | Hutchmed | Relapsed/Refractory Lymphoma | 05/26 | 12/26 | | |
NCT04908046: A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Completed | 1 | 47 | RoW | HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days . | Hutchmed | Advanced Malignant Solid Tumors | 01/24 | 02/24 | | |
NCT06433531: A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) |
|
|
| Recruiting | 1 | 10 | RoW | TQH2929 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Generalized Pustular Psoriasis | 02/25 | 02/25 | | |
NCT05886374: A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 81 | RoW | HMPL-415S1 | Hutchmed | Advanced Malignant Solid Tumors | 05/25 | 06/26 | | |
| Not yet recruiting | N/A | 5000 | RoW | Endovascular Therapy | Chinese Academy of Medical Sciences, Fuwai Hospital | Renal Artery Obstruction, Hypertension, Renovascular | 04/22 | 04/24 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
NCT06221722: Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation |
|
|
| Recruiting | N/A | 150 | RoW | BOLD-fMRI, Regular treatment of functional constipation, fluoxetine | Xijing Hospital of Digestive Diseases | Constipation - Functional, Refractory Constipation, Fluoxetine, fMRI, Brain Connectivity, Treatment Efficacy, Somatic Symptom, Mental Symptom | 09/25 | 09/26 | | |
| Not yet recruiting | N/A | 1500 | RoW | adrenal venous sampling | Chinese Academy of Medical Sciences, Fuwai Hospital | Hyperaldosteronism | 12/26 | 12/26 | | |
| Recruiting | N/A | 320 | RoW | No intervention | The First Affiliated Hospital of Xiamen University | Rebound Pain, Arthroscopic Knee Surgery, Oliceridine | 12/25 | 12/25 | | |
NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis |
|
|
| Recruiting | N/A | 188 | RoW | Ton-bridge carotid stent, WALLSTENT carotid stent | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Carotid Artery Stenosis | 11/24 | 10/25 | | |
FLAVOUR II, NCT04397211: Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease |
|
|
| Active, not recruiting | N/A | 1872 | RoW | Angiography-derived FFR, IVUS | Second Affiliated Hospital, School of Medicine, Zhejiang University, Seoul National University Hospital, Affiliated Hangzhou First People's Hospital, Wuhan University, Peking University Third Hospital, The Affiliated Hospital of Hangzhou Normal University, RenJi Hospital, Second Hospital of Shanxi Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Changxing People's Hospital, The Affiliated Hospital of Medical College, Ningbo University, Jinhua Central Hospital, Shandong University of Traditional Chinese Medicine, Dongyang People's Hospital, The First Affiliated Hospital of Nanchang University, Jining First People's Hospital, Second Affiliated Hospital of Shantou University Medical College, Ulsan University Hospital, Huizhou Municipal Central Hospital, Zhejiang Greentown Cardiovascular Hospital, The Fourth People's Hospital of Jinan, First Affiliated Hospital of Kunming Medical University | Coronary Artery Disease | 09/24 | 09/28 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
NCT05410652: Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method) |
|
|
| Completed | N/A | 1176 | RoW | Detection of fecal samples with diagnostic kit, Sanger Sequencing group, Bacterial culture and drug sensitivity test of gastric mucosa samples | Nanjing First Hospital, Nanjing Medical University | Helicobacter Pylori Infection, Helicobacter Pylori gyrA Levofloxacin Resistance Mutation, Fecal Drug Resistance Gene Detection, Helicobacter Pylori Infection, Susceptibility to | 09/23 | 10/23 | | |
